Ibnsina Pharma

Ibnsina Pharma originally established in 2001, today Ibnsina Pharma is Egypt’s fastest-growing and second largest pharmaceutical distribution company. The Company distributes a competitive portfolio of pharmaceutical products from over 350 Egyptian and multinational pharmaceutical companies to more than 42,000 customers including pharmacies, hospitals, retail outlets and wholesalers. Its fleet of around 650 vehicles completes an average of over 460,000 deliveries each month. Ibnsina Pharma’s core services for suppliers include management of warehousing and logistics for pharmaceutical products as well as the development and execution of tailored marketing solutions targeting a nationwide database of customers. The Company also provides efficient and reliable order-taking and delivery services to customers and was the first in its industry to pioneer a telesales model. Operating across 59 sites in 23 cities nationwide, Ibnsina Pharma’s team of more than 5,500 employees is dedicated to improving people’s quality of life by ensuring their access to safe and high quality pharmaceutical products.

Related News

PHARMACY MARKET

LUBRIZOL LIFE SCIENCE LAUNCHES ADVANCED, NATURAL NUTRACEUTICAL SOLUTION TO SUPPORT MENTAL AGILITY

Lubrizol Life Science | October 28, 2020

news image

Lubrizol Life Science Health (LLS Health) launches ASTAGILE™ microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina. The two ingredients have been uniquely combined in a patent-pending product designed to promote mental agility and support healthy ageing for young and senior adults. Astaxanthin is a carotenoid found in freshwater microalgae, and spirulina is a type of algae. Both have numerous health promoting effects....

Read More

PHARMACY MARKET

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma | January 05, 2021

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More

PHARMACY MARKET

VIRPAX PHARMACEUTICALS RECAPS MILESTONES AND HIGHLIGHTS PRODUCT PORTFOLIO

Virpax® Pharmaceuticals, Inc. | December 29, 2021

news image

Virpax® Pharmaceuticals, Inc. "Company" achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I believe that Virpax has made significant progress this past year toward our stated goalsThese accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently...

Read More

MEDICURE ANNOUNCES TERMINATION OF REDS™ PRO MARKETING AND DISTRIBUTION AGREEMENT

Prnewswire | August 20, 2020

news image

Medicure Inc. a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. ("Sensible") for the marketing of the ReDSTM Pro ("ReDS Pro") device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure. Medicure continues to hold a 7....

Read More
news image

PHARMACY MARKET

LUBRIZOL LIFE SCIENCE LAUNCHES ADVANCED, NATURAL NUTRACEUTICAL SOLUTION TO SUPPORT MENTAL AGILITY

Lubrizol Life Science | October 28, 2020

Lubrizol Life Science Health (LLS Health) launches ASTAGILE™ microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina. The two ingredients have been uniquely combined in a patent-pending product designed to promote mental agility and support healthy ageing for young and senior adults. Astaxanthin is a carotenoid found in freshwater microalgae, and spirulina is a type of algae. Both have numerous health promoting effects....

Read More
news image

PHARMACY MARKET

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma | January 05, 2021

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More
news image

PHARMACY MARKET

VIRPAX PHARMACEUTICALS RECAPS MILESTONES AND HIGHLIGHTS PRODUCT PORTFOLIO

Virpax® Pharmaceuticals, Inc. | December 29, 2021

Virpax® Pharmaceuticals, Inc. "Company" achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I believe that Virpax has made significant progress this past year toward our stated goalsThese accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently...

Read More
news image

MEDICURE ANNOUNCES TERMINATION OF REDS™ PRO MARKETING AND DISTRIBUTION AGREEMENT

Prnewswire | August 20, 2020

Medicure Inc. a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. ("Sensible") for the marketing of the ReDSTM Pro ("ReDS Pro") device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure. Medicure continues to hold a 7....

Read More